Today: 27 June 2026
Wilmar stock rises in Singapore as palm oil firms — what investors are watching next
22 January 2026
1 min read

Wilmar stock rises in Singapore as palm oil firms — what investors are watching next

Singapore, Jan 22, 2026, 15:29 SGT — Regular session

  • Wilmar shares climbed in afternoon trading, outperforming the Straits Times Index.
  • A steady buzz around exports and stronger palm oil prices kept agribusiness stocks in the spotlight.
  • Wilmar’s full-year results, due in February, stand out as the next major catalyst.

Wilmar International Ltd shares climbed 1.6% to S$3.23 by 3:28 p.m. in Singapore, ranking among the Straits Times Index’s top gainers as the benchmark edged up 0.3%. The stock fluctuated between S$3.17 and S$3.24, with roughly 5.2 million shares traded.

This shift is significant since Wilmar is a key player in the edible-oils market. Palm oil price swings often trigger a reevaluation across the entire supply chain — spanning plantations, refining, and consumer-pack oils — despite the complicated connection to actual earnings.

The move comes as traders seek clearer cues for the Lunar New Year demand window, a timeframe that often reshapes buying behavior in cooking oils and related commodities, particularly across Asia.

Palm oil futures in Kuala Lumpur hit a seven-week peak on Tuesday, with the April contract climbing 1.47% to 4,154 ringgit per metric ton, Reuters reported. David Ng, a proprietary trader at Iceberg X Sdn Bhd, attributed the gains to “strong demand” expectations ahead of the holiday season. Meanwhile, cargo surveyors reported Malaysia’s palm oil exports for January 1–20 rose between 8.64% and 11.4% compared to the previous month. Business Recorder

Palm oil frequently tracks rival oils like soy oil, since buyers will switch feedstocks if prices stray too far. Its role in biodiesel means energy prices and policy discussions also influence the market.

Wilmar grabbed some attention Thursday when The Business Times reported it landed on Fortune’s 2026 World’s Most Admired Companies list, placing fourth in the global food production sector.

Investors face a near-term checkpoint: Wilmar announced to the Singapore Exchange that its full-year financial results for the year ending Dec. 31, 2025, will be published after market close on Feb. 26.

Wilmar stands as one of Asia’s largest agribusiness giants, covering everything from oil palm cultivation to oilseed crushing, edible oils refining, and food products. This wide scope offers some protection against shocks, but it also causes the group’s margins to shift unevenly across segments when commodity prices fluctuate.

The downside risk is clear. Should palm oil prices drop or holiday demand fall short, the commodity-driven boost to sentiment could vanish fast, dragging the stock back down with the broader market.

Traders are keeping an eye on new export data and palm oil price moves heading into month-end. Wilmar’s next big date is Feb. 26, when it’s scheduled to release full-year results after markets close.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Nvidia Invests in AI-Driven Biotechnology Firm Generate Biomedicines, Targeting $1.8 Trillion Pharma Market
    June 27, 2026, 9:17 AM EDT. Nvidia (NASDAQ: NVDA) has acquired 833,325 shares in Generate Biomedicines (NASDAQ: GENB), a $2 billion market cap biotechnology company using AI to digitally test drug molecules. This minority stake reflects Nvidia's confidence in GENB's AI platform, which accelerates drug discovery by simulating molecule performance before costly clinical trials. Generate's pipeline includes four drug candidates, with one in phase 3 testing for severe asthma. Nvidia's venture capital arm NVentures' $13 million investment aligns with the tech giant's expertise in AI hardware, highlighting the growing convergence of AI and biopharma. The move positions Generate Biomedicines to potentially disrupt the $1.8 trillion pharmaceutical market by reducing drug development time and costs, addressing key industry challenges.

Latest articles

Oil Prices Today: Brent Whipsaws as Iran Peace Hopes Hit OPEC Supply Shock

Funds trim WTI longs, Hormuz supply flows ease squeeze from tight U.S. stocks

27 June 2026
Brent crude plunged 10.86% this week to $71.99 as funds slashed net long WTI positions by 13,356 contracts, despite Cushing inventories hitting their lowest since 2014 and U.S. diesel margins surging; investors face key risks from Hormuz traffic, U.S.-Iran tensions, OPEC+ output hikes, and China’s fuel export boost.
AI stocks eye $41 billion tech-fund shift as memory costs hit

AI stocks eye $41 billion tech-fund shift as memory costs hit

27 June 2026
Technology sector funds saw nearly $20 billion in outflows the week to June 24—erasing the prior week’s $21.46 billion inflows—just before chip stocks plunged, with the Nasdaq dropping 4.6% and the Philadelphia semiconductor index posting its worst week since April, as investors questioned AI profitability and shifted away from tech.
IPO calendar eyes Bending Spoons as shortened week thins deal pipeline

IPO calendar eyes Bending Spoons as shortened week thins deal pipeline

27 June 2026
Bending Spoons (NASDAQ:BSP) drives 61% of next week’s $2.56 billion U.S. IPO proceeds, making its $1.57 billion raise a key test for investor appetite in debt-heavy software M&A, with a $18.1 billion valuation and 4.0x net debt to EBITDA leverage, as markets brace for a holiday-shortened week and a looming $29.4 billion SK hynix Nasdaq ADR.
UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals
Previous Story

UPL share price slips as Advanta IPO papers hit SEBI: what the filing reveals

Salesforce stock rebounds as Dow firms; Benioff’s Davos AI warning keeps CRM in focus
Next Story

Salesforce stock rebounds as Dow firms; Benioff’s Davos AI warning keeps CRM in focus

Go toTop